Introduction {#H1-1-ZOI190006}
============

The prevalence of adult obesity in the United States is expected to reach approximately 50% by 2030.^[@zoi190006r1]^ Obesity is the most common risk factor for nonalcoholic fatty liver disease and the progressive subtype of the disease, nonalcoholic steatohepatitis (NASH), which can give rise to cirrhosis and hepatocellular carcinoma (HCC). In recent prospective studies, more than 70% of patients with compensated cirrhosis were overweight or obese.^[@zoi190006r2]^ In addition to contributing to the development of advanced liver disease, obesity also leads to worse outcomes among patients with compensated cirrhosis. Compared with their normal-weight counterparts, obese patients with compensated cirrhosis face a nearly 3-fold increased risk of decompensation.^[@zoi190006r2]^

Weight loss can be an effective treatment for NASH.^[@zoi190006r3]^ In a recent 12-month trial of lifestyle interventions, fibrosis improved or stabilized in patients with NASH who lost at least 5% of total body weight.^[@zoi190006r4]^ Weight loss through diet and exercise also decreases portal pressure in patients with NASH and compensated cirrhosis, which likely reduces the likelihood of decompensation.^[@zoi190006r5]^ In addition, weight loss may also improve the likelihood of receiving a liver transplant for patients on the wait list.^[@zoi190006r6]^ Although diet and exercise may improve outcomes in patients with NASH, long-term maintenance of weight loss is often inadequate. In a trial of lifestyle intervention in patients with NASH, only 50% achieved 7% total body weight loss after 1 year.^[@zoi190006r4]^

In contrast with lifestyle interventions, bariatric surgery often induces excellent long-term weight loss outcomes and may also have the potential to halt or reverse liver damage in cirrhosis.^[@zoi190006r7],[@zoi190006r8]^ However, bariatric surgery carries heightened perioperative risks in patients with cirrhosis. An analysis of patients undergoing bariatric surgery in the Nationwide Inpatient Sample showed that mortality was higher in those with compensated (0.9%) and decompensated cirrhosis (16.3%) than in those without cirrhosis (0.3%).^[@zoi190006r9]^ In addition, the cost of bariatric surgery may pose a potential barrier for some patients; payers typically deny coverage of these procedures to individuals with body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of less than 35.0, making surgery inaccessible to many who might benefit from it.

Despite the benefits of weight loss in NASH cirrhosis and the increasing burden of this condition, no randomized clinical trial has been performed, to date, to assess the effect of bariatric surgery and nonsurgical weight loss interventions on the progression of advanced liver disease. Under these circumstances, mathematical modeling provides a platform to integrate the best available data to help guide medical decision making. The aim of our study was to perform a comparative cost-effectiveness analysis of bariatric surgery in patients with NASH cirrhosis who were overweight or obese.

Methods {#H1-2-ZOI190006}
=======

Model Structure {#H2-1-ZOI190006}
---------------

This report follows the Consolidated Health Economic Evaluation Reporting Standards ([CHEERS](http://www.equator-network.org/reporting-guidelines/cheers/)) reporting guideline for economic evaluations. We developed a Markov-based state-transition model using TreeAge Pro software (version 2017; TreeAge) to assess cost-effectiveness of the following 4 different weight loss strategies: usual care, intensive lifestyle intervention (ILI), laparoscopic sleeve gastrectomy (SG), and laparoscopic Roux-en-Y gastric bypass (GB) ([Figure](#zoi190006f1){ref-type="fig"}). Institutional review board approval was not required for this study that did not use human participants.

![Simplified Model Schematic\
The dashed line between the compensated cirrhosis and decompensated cirrhosis states indicates that the probability of decompensating varies according to body mass index and thus decreases with weight loss. ICER indicates incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years.](jamanetwopen-2-e190047-g001){#zoi190006f1}

The baseline patient characteristics of the simulated population were based on a previously published prospective study^[@zoi190006r2]^ (n = 161). Patients in the model were 41.0% female, and the base case age was 54 years. Note that this population represents patients with cirrhosis and thus includes a higher proportion of older and male individuals than the overall population of patients undergoing bariatric surgery. Our analysis was conducted for patients with overweight, mild obesity, moderate obesity, and severe obesity. The model cycle length, or time between state transitions, was 1 year. Each year, patients could remain in the same health state, progress to another, or die. Patients with compensated cirrhosis could progress to the decompensated cirrhosis state. Based on an analysis that associated obesity with clinical decompensation,^[@zoi190006r2]^ we adjusted the probability of decompensation according to patients' BMI. Patients with compensated or decompensated cirrhosis could progress to HCC.^[@zoi190006r10],[@zoi190006r11],[@zoi190006r12],[@zoi190006r13],[@zoi190006r14]^ In the model, liver transplant was a possibility only for individuals with decompensated cirrhosis or HCC ([Figure](#zoi190006f1){ref-type="fig"}).^[@zoi190006r15],[@zoi190006r16],[@zoi190006r17],[@zoi190006r18]^ After transplant, these patients faced a risk of death based on mortality rates among transplant recipients.^[@zoi190006r19]^ Possible causes of death included surgical mortality, liver-related mortality, and background mortality, which was based on patients' age, sex, and BMI, using data from the US Third National Health and Nutritional Examination Survey.^[@zoi190006r9],[@zoi190006r20],[@zoi190006r21],[@zoi190006r22],[@zoi190006r23]^ Patients with compensated and decompensated cirrhosis had excess liver-related mortality of 2.1% and 13.0%, respectively.^[@zoi190006r11],[@zoi190006r12],[@zoi190006r22]^ Simulated patients were followed up until death, to capture the long-term benefits of surgery.

Competing Strategies {#H2-2-ZOI190006}
--------------------

In the usual-care strategy, patients did not undergo surgery or other weight loss interventions, and their liver disease progressed according to probabilities derived from the literature. We assumed that, without intervention, patients' weight remained constant during their lifetime.

In SG and GB strategies, patients faced a risk of 30-day surgical mortality after the operation, which varied depending on the type of procedure, based on the American College of Surgeons National Quality Improvement Survey.^[@zoi190006r23]^ They also encountered the possibility of major and minor complications after surgery.^[@zoi190006r23]^ Major complications required a second operation; minor complications required readmission but no additional operation. The estimates from the American College of Surgeons National Quality Improvement Survey were adjusted for our population using data from a study that compared mortality in patients with compensated cirrhosis and patients without cirrhosis.^[@zoi190006r9]^

After surgery, patients underwent weight loss, which could slow the progression of liver disease in our model by decreasing the probability of decompensation. We incorporated the association of weight loss with survival and quality of life for patients in the following 4 weight classes: overweight (BMI, 25.0-29.9), mild obesity (BMI, 30.0-34.9), moderate obesity (BMI, 35.0-39.9), and severe obesity (BMI, ≥40.0). Postsurgical weight loss was derived from a recent meta-analysis.^[@zoi190006r24]^ Weight loss in the ILI strategy was derived from the Look AHEAD (Action for Health in Diabetes) trial.^[@zoi190006r25]^ Long-term trends in weight were extrapolated using data from the Swedish Obese Subjects study.^[@zoi190006r26]^ We applied our estimates of percentage of excess weight loss (eTable 1 in the [Supplement](#note-ZOI190006-1-s){ref-type="supplementary-material"}) to all of the initial weight categories in our analysis.

Costs and Quality-of-Life Adjustments {#H2-3-ZOI190006}
-------------------------------------

Costs associated with treatment strategies, surgical complications, and health states were derived from the literature.^[@zoi190006r27],[@zoi190006r28],[@zoi190006r29],[@zoi190006r30],[@zoi190006r31],[@zoi190006r32]^ The initial cost of GB was based on a prior analysis,^[@zoi190006r27]^ and the cost of SG was calculated using cost data from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample.^[@zoi190006r28]^ All costs from prior years were converted to 2017 \$US using the Consumer Price Index.^[@zoi190006r33]^ Costs were evaluated from the perspective of a third-party payer.

Utility estimates were derived from studies on cirrhosis due to other causes because no quality-of-life studies for NASH cirrhosis were available to inform our model.^[@zoi190006r34]^ This approach has been used in a previous cost-effectiveness analysis studying NASH.^[@zoi190006r10]^ All patients who underwent surgery had a decrement in their quality of life, which was applied for 6 weeks. An additional quality-of-life decrement was applied for 6 weeks to patients who experienced major complications, and a 4-week decrement was applied after mild complications. Complications also incurred additional costs.^[@zoi190006r27]^ We adjusted quality of life based on patients' age, sex, and weight class (eTable 2 in the [Supplement](#note-ZOI190006-1-s){ref-type="supplementary-material"}). Costs and utilities were discounted at an annual rate of 3%.^[@zoi190006r35]^

Outcomes {#H2-4-ZOI190006}
--------

Compared with usual care, we estimated the gain in life-years, quality-adjusted life-years (QALYs), and total costs for patients undergoing ILI, SG, and GB. We assessed cost-effectiveness for each treatment strategy by estimating incremental cost-effectiveness ratios (ICERs) for patients with overweight, mild obesity, moderate obesity, and severe obesity. The ICERs were calculated on an efficiency frontier. The willingness-to-pay threshold to determine cost-effectiveness was \$100 000 per QALY.

Sensitivity Analysis {#H2-5-ZOI190006}
--------------------

Data were collected on March 22, 2017. We conducted 1-way sensitivity analyses to examine the association of model parameter uncertainty on the cost-effectiveness results for patients in each weight class. One-way sensitivity analyses were performed for the cost-effective strategy in each weight class (ie, SG). We also performed probabilistic sensitivity analysis (PSA) to assess how model parameter uncertainty could affect our results. In PSA, all parameter values were varied simultaneously, using statistical distributions derived from the literature ([Table 1](#zoi190006t1){ref-type="table"}). We conducted PSA using second-order sampling for 10 000 iterations for each weight class.

###### Model Inputs: Baseline Values, Ranges, and Parameters for Distributions Used in Deterministic and Probabilistic Sensitivity Analyses

  Parameter                                                                                          Source                                                                                                                                                                                    Base Case (Range or Variation)   Distribution   Parameter 1[^a^](#zoi190006t1n1){ref-type="table-fn"}   Parameter 2[^b^](#zoi190006t1n2){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------- -------------- ------------------------------------------------------- -------------------------------------------------------
  Age, y                                                                                             Berzigotti et al,^[@zoi190006r2]^ 2011                                                                                                                                                    54 (34.4 to 73.6)                NA             NA                                                      NA
  Female, %                                                                                          Berzigotti et al,^[@zoi190006r2]^ 2011                                                                                                                                                    41 (35 to 49)                    β              59.122                                                  85.078
  Annual discount rate, %                                                                            Weinstein et al,^[@zoi190006r35]^ 1996                                                                                                                                                    3 (0 to 5)                       β              8.354                                                   270.122
  Transition probabilities                                                                                                                                                                                                                                                                                                                                                                             
  HR per 1-U increase in BMI                                                                         Berzigotti et al,^[@zoi190006r2]^ 2011                                                                                                                                                    1.06 (1.01 to 1.12)              Log normal     4.907                                                   86.682
  CC to DC (BMI, 27.2), %                                                                            NA                                                                                                                                                                                        7.21 (3.21 to 10.77)             β              13.0128                                                 167.469
  CC/DC to HCC, %^[@zoi190006r10],[@zoi190006r11],[@zoi190006r12],[@zoi190006r13],[@zoi190006r14]^   Mahady et al,^[@zoi190006r10]^ 2012; Sanyal et al,^[@zoi190006r11]^ 2006; Ratziu et al,^[@zoi190006r12]^ 2002; Ascha et al,^[@zoi190006r13]^ 2010; Yatsuji et al,^[@zoi190006r14]^ 2009   0.69 (0.50 to 16.8)              β              1.03                                                    147.97
  CC to liver-related death, %                                                                       Sanyal et al,^[@zoi190006r11]^ 2006; Hui et al,^[@zoi190006r22]^ 2003                                                                                                                     2.1 (2.0 to 4.0)                 β              4.483                                                   210.003
  DC to liver-related death, %                                                                       Ratziu et al,^[@zoi190006r12]^ 2002                                                                                                                                                       13.0 (10.0 to 38.0)              β              0.774                                                   5.178
  HCC to liver-related death, %                                                                      Fattovich et al,^[@zoi190006r21]^ 2002                                                                                                                                                    42.7 (33.0 to 86.0)              β              2.14                                                    2.87
  DC to transplantation, %                                                                           Thuluvath et al,^[@zoi190006r15]^ 2010; Davis et al,^[@zoi190006r16]^ 2011                                                                                                                2.3 (1.0 to 6.2)                 β              1.282                                                   54.473
  HCC to transplantation, %                                                                          Lang et al,^[@zoi190006r17]^ 2009; Saab et al,^[@zoi190006r18]^ 2010                                                                                                                      4.0 (0.0 to 14.0)                β              0.59                                                    14.16
  Posttransplant to liver-related death in year 1, %                                                 Wolfe et al,^[@zoi190006r19]^ 2010                                                                                                                                                        11.6 (6.0 to 42.0)               β              0.38                                                    2.88
  Posttransplant to liver-related death in year 2 or later, %^[@zoi190006r19]^                       Wolfe et al,^[@zoi190006r19]^ 2010                                                                                                                                                        4.4 (2.4 to 11.0)                β              1.59                                                    34.51
  30-Day mortality for GB, %                                                                         Mosko and Nguyen,^[@zoi190006r9]^ 2011; Young et al,^[@zoi190006r23]^ 2015                                                                                                                0.3255 (0.10 to 1.00)            β              2.000                                                   612.491
  30-Day mortality for SG, %                                                                         Mosko and Nguyen,^[@zoi190006r9]^ 2011; Young et al,^[@zoi190006r23]^ 2015                                                                                                                0.217 (0.041 to 1.14)            β              0.596                                                   273.886
  Minor complications for GB, %                                                                      Mosko and Nguyen,^[@zoi190006r9]^ 2011; Young et al,^[@zoi190006r23]^ 2015                                                                                                                7.86 (3.73 to 16.47)             β              5.311                                                   62.255
  Major complications for GB, %                                                                      Mosko and Nguyen,^[@zoi190006r9]^ 2011; Young et al,^[@zoi190006r23]^ 2015                                                                                                                5.34 (2.53 to 11.19)             β              5.477                                                   97.095
  Minor complications for SG, %                                                                      Mosko and Nguyen,^[@zoi190006r9]^ 2011; Young et al,^[@zoi190006r23]^ 2015                                                                                                                5.32 (2.52 to 11.15)             β              5.476                                                   97.449
  Major complications for SG, %                                                                      Mosko and Nguyen,^[@zoi190006r9]^ 2011; Young et al,^[@zoi190006r23]^ 2015                                                                                                                3.47 (1.65 to 7.28)              β              5.600                                                   155.785
  Health-related quality-of-life weights                                                                                                                                                                                                                                                                                                                                                               
  CC                                                                                                 Chhatwal et al,^[@zoi190006r34]^ 2015                                                                                                                                                     0.90 (0.81 to 0.99)              Β              37.52                                                   4.17
  DC                                                                                                 Chhatwal et al,^[@zoi190006r34]^ 2015                                                                                                                                                     0.80 (0.57 to 0.99)              β              8.50                                                    2.12
  HCC                                                                                                Chhatwal et al,^[@zoi190006r34]^ 2015                                                                                                                                                     0.79 (0.54 to 0.99)              β              7.27                                                    1.93
  Liver transplant at year 1                                                                         Chhatwal et al,^[@zoi190006r34]^ 2015                                                                                                                                                     0.84 (0.77 to 0.93)              β              52.70                                                   10.04
  Liver transplant at year 2 or later                                                                Chhatwal et al,^[@zoi190006r34]^ 2015                                                                                                                                                     0.93 (0.84 to 0.99)              β              27.78                                                   2.09
  Treatment-related quality-of-life weights                                                                                                                                                                                                                                                                                                                                                            
  Initial surgery                                                                                    Campbell et al,^[@zoi190006r27]^ 2010                                                                                                                                                     --0.22 (--0.24 to --0.20)        β              300.96                                                  1067.03
  Minor complications                                                                                Campbell et al,^[@zoi190006r27]^ 2010                                                                                                                                                     --0.11 (--0.12 to --0.10)        β              369.31                                                  2988.03
  Major complications                                                                                Campbell et al,^[@zoi190006r27]^ 2010                                                                                                                                                     --0.36 (--0.40 to --0.32)        β              258.87                                                  460.21
  Weight-related quality-of-life weights                                                                                                                                                                                                                                                                                                                                                               
  BMI \<30.0                                                                                         Campbell et al,^[@zoi190006r27]^ 2010                                                                                                                                                     0.88 (0.79 to 0.97)              β              48.22                                                   6.58
  BMI 30.0-34.9                                                                                      Campbell et al,^[@zoi190006r27]^ 2010                                                                                                                                                     0.85 (0.77 to 0.93)              β              60.27                                                   10.64
  BMI 35.0-39.9                                                                                      Campbell et al,^[@zoi190006r27]^ 2010                                                                                                                                                     0.82 (0.74 to 0.90)              β              72.33                                                   15.88
  BMI ≥40.0                                                                                          Campbell et al,^[@zoi190006r27]^ 2010                                                                                                                                                     0.78 (0.70 to 0.86)              β              88.40                                                   24.93
  Health state costs, 2017 \$US                                                                                                                                                                                                                                                                                                                                                                        
  CC                                                                                                 Saab et al,^[@zoi190006r30]^ 2014; Gordon et al,^[@zoi190006r31]^ 2012; McAdam-Marx et al,^[@zoi190006r32]^ 2011                                                                          \$5886 (±25%)                    γ              61.466                                                  0.010
  DC                                                                                                 Saab et al,^[@zoi190006r30]^ 2014; Gordon et al,^[@zoi190006r31]^ 2012; McAdam-Marx et al,^[@zoi190006r32]^ 2011                                                                          \$41 082 (±25%)                  γ              61.466                                                  0.001
  HCC                                                                                                Saab et al,^[@zoi190006r30]^ 2014; Gordon et al,^[@zoi190006r31]^ 2012; McAdam-Marx et al,^[@zoi190006r32]^ 2011                                                                          \$90 344 (±25%)                  γ              61.466                                                  6.804
  Liver transplant year 1                                                                            Saab et al,^[@zoi190006r30]^ 2014; Gordon et al,^[@zoi190006r31]^ 2012; McAdam-Marx et al,^[@zoi190006r32]^ 2011                                                                          \$183 279 (±25%)                 γ              61.466                                                  3.354
  Liver transplant year 2 or later                                                                   Saab et al,^[@zoi190006r30]^ 2014; Gordon et al,^[@zoi190006r31]^ 2012; McAdam-Marx et al,^[@zoi190006r32]^ 2011                                                                          \$45 107 (±25%)                  γ              61.466                                                  0.001
  Treatment costs, 2017 \$US                                                                                                                                                                                                                                                                                                                                                                           
  GB                                                                                                 Campbell et al,^[@zoi190006r27]^ 2010; AHRQ,^[@zoi190006r28]^ 2014                                                                                                                        \$28 734 (±25%)                  γ              61.466                                                  0.002
  SG                                                                                                 Campbell et al,^[@zoi190006r27]^ 2010; AHRQ,^[@zoi190006r28]^ 2014                                                                                                                        \$23 660 (±25%)                  γ              61.466                                                  0.003
  Minor complications                                                                                Campbell et al,^[@zoi190006r27]^ 2010                                                                                                                                                     \$1414 (±25%)                    γ              61.466                                                  0.043
  Major complications                                                                                Campbell et al,^[@zoi190006r27]^ 2010                                                                                                                                                     \$46 091 (±25%)                  γ              61.466                                                  0.001
  ILI in year 1                                                                                      Rushing et al,^[@zoi190006r29]^ 2017                                                                                                                                                      \$1410 (±25%)                    γ              61.466                                                  0.044
  ILI in year 2                                                                                      Rushing et al,^[@zoi190006r29]^ 2017                                                                                                                                                      \$1087 (±25%)                    γ              61.466                                                  0.057
  ILI in year 3                                                                                      Rushing et al,^[@zoi190006r29]^ 2017                                                                                                                                                      \$932 (±25%)                     γ              61.466                                                  0.067
  ILI in year 4                                                                                      Rushing et al,^[@zoi190006r29]^ 2017                                                                                                                                                      \$750 (±25%)                     γ              61.466                                                  0.083
  ILI in years 5-8                                                                                   Rushing et al,^[@zoi190006r29]^ 2017                                                                                                                                                      \$564 (±25%)                     γ              61.466                                                  0.111

Abbreviations: AHRQ, Agency for Healthcare Research and Quality; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CC, compensated cirrhosis; DC, decompensated cirrhosis; GB, laparoscopic Roux-en-Y gastric bypass; HCC, hepatocellular carcinoma; HR, hazard ratio; ILI, intensive lifestyle intervention; NA, not applicable; SG, laparoscopic sleeve gastrectomy.

Corresponds to the α parameter for β distribution, the k (shape) parameter for γ distribution, and μ for log normal distribution.

Corresponds to the β parameter for β distribution, θ (scale) parameter for γ distribution, and α for log normal distribution.

Results {#H1-3-ZOI190006}
=======

Base-Case Results {#H2-6-ZOI190006}
-----------------

All weight loss strategies involved a gain in life-years and QALYs in patients with compensated cirrhosis (41% female and 59% male; base case age, 54 years). Compared with usual care, SG was associated with an increase in QALYs of 0.263 to 1.180 (bounds of ranges represent overweight to severe obesity); GB, 0.263 to 1.207; and ILI, 0.004 to 0.216. Sleeve gastrectomy was also associated with an increase in life-years of 0.693 to 1.930; GB, 0.694 to 1.947; and ILI, 0.012 to 0.114 ([Table 2](#zoi190006t2){ref-type="table"}). With usual care, expected life-years in overweight, mild obesity, moderate obesity, and severe obesity were 12.939, 11.949, 10.976, and 10.095, respectively. These results are consistent with prospective studies that found median survival of greater than 12 years in patients with compensated cirrhosis.^[@zoi190006r36]^ With usual care, QALY in overweight was 6.418; mild obesity, 5.790; moderate obesity, 5.186; and severe obesity, 4.577. For patients with obesity (mild, moderate, and severe), GB involved the greatest increase in life-years and QALYs, followed by SG and then ILI. In contrast, for overweight patients, GB had the largest increase in life-years; however, SG had the largest increase in QALYs, followed very closely by GB and then by ILI. Note that these differences between GB and SG for overweight patients were very small. When rounded to the nearest thousandth, SG and GB both involved an equal number of QALYs, and GB involved 0.001 additional life-years compared with SG.

###### Results of Cost-effectiveness Analyses[^a^](#zoi190006t2n1){ref-type="table-fn"}

  Strategy                           Cost, 2017 \$US   Incremental Cost, 2017 \$US   QALYs   Incremental QALYs   Life-Years   Incremental Life-Years   ICER, \$/QALY
  ---------------------------------- ----------------- ----------------------------- ------- ------------------- ------------ ------------------------ ----------------------
  Severe obesity (BMI ≥40.0)                                                                                                                           
  Usual care                         214 412           NA                            4.577   NA                  10.095       NA                       NA
  ILI                                223 087           934                           4.793   −0.964              10.209       −1.815                   Absolutely dominated
  SG                                 222 153           7741                          5.757   1.179               12.025       1.930                    6563
  GB                                 228 369           6216                          5.784   0.027               12.042       0.017                    229 919
  Moderate obesity (BMI 35.0-39.9)                                                                                                                     
  Usual care                         206 809           NA                            5.186   NA                  10.976       NA                       NA
  ILI                                214 953           8145                          5.259   0.073               11.063       0.087                    Extendedly dominated
  SG                                 216 075           1122                          6.088   0.829               12.593       1.530                    10 274
  GB                                 222 174           6099                          6.106   0.019               12.604       0.011                    329 002
  Mild obesity (BMI 30.0-34.9)                                                                                                                         
  Usual care                         197 486           NA                            5.790   NA                  11.949       NA                       NA
  ILI                                205 128           7642                          5.809   0.020               12.001       0.052                    Extendedly dominated
  SG                                 209 976           4848                          6.457   0.648               13.131       1.130                    18 716
  GB                                 215 990           6014                          6.458   0.002               13.137       0.006                    3 667 701
  Overweight (BMI 25.0-29.9)                                                                                                                           
  Usual care                         186 264           NA                            6.418   NA                  12.939       NA                       NA
  ILI                                193 506           7242                          6.422   0.004               12.951       0.012                    Extendedly dominated
  SG                                 203 660           10 153                        6.681   0.258               13.632       0.681                    66 119
  GB                                 209 606           5946                          6.681   0                   13.633       0.001                    Absolutely dominated

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); GB, laparoscopic Roux-en-Y gastric bypass; ICER, incremental cost-effectiveness ratio; ILI, intensive lifestyle intervention; NA, not applicable; QALYs, quality-adjusted life-years; SG, laparoscopic sleeve gastrectomy.

An extendedly dominated strategy has an ICER that is higher than that of the next most effective strategy. An absolutely dominated strategy is more expensive and less effective than other strategies. Note that the ILI strategy has negative incremental QALYs and life-years for the severe obesity category; as the ILI strategy was absolutely dominated, the incremental QALYs, life-years, and costs for this group are calculated against the SG strategy.

Cost-effectiveness analysis found that SG was the optimal strategy in patients with NASH cirrhosis in all weight categories. Compared with the next nondominated strategy, the ICER for SG was \$66 119 per QALY in overweight, \$18 716 per QALY in mild obesity, \$10 274 per QALY in moderate obesity, and \$6563 per QALY in severe obesity ([Table 2](#zoi190006t2){ref-type="table"}). Although GB involved a greater increase in QALYs than SG in obese patients, GB was also more expensive, and the ICER for GB (\$229 919 per QALY for severe, \$329 002 per QALY for moderate, and \$3 667 701 per QALY for mild obesity) exceeded the commonly accepted willingness-to-pay threshold of \$100 000 per QALY.

A threshold analysis on the procedure cost of GB found that for GB to be cost-effective, the cost of the surgery must be decreased from its baseline value of \$28 734 by \$4889 for mild obesity, by \$3189 for moderate obesity, and by \$2289 for severe obesity ([Table 3](#zoi190006t3){ref-type="table"}). In overweight patients, GB involved fewer QALYs than SG, and thus decreasing the cost of surgery would not result in cost-effectiveness.

###### Threshold Analysis: Procedure Cost That Could Make GB Cost-effective[^a^](#zoi190006t3n1){ref-type="table-fn"}

  Patient Profile                    Reduced Cost of GB at Which GB Is the Most Cost-effective Intervention \$   Cost Reduction Relative to Baseline Cost of GB, 2017 \$US
  ---------------------------------- --------------------------------------------------------------------------- -----------------------------------------------------------
  Severe obesity (BMI ≥40.0)         25 965                                                                      2289
  Moderate obesity (BMI 35.0-39.9)   25 065                                                                      3189
  Mild obesity (BMI 30.0-34.9)       23 365                                                                      4889

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); GB, laparoscopic Roux-en-Y gastric bypass.

Baseline cost of GB was \$28 734. Overweight is not included because GB was absolutely dominated for this BMI class (ie, GB resulted in fewer quality-adjusted life-years than sleeve gastrectomy).

Sensitivity Analysis {#H2-7-ZOI190006}
--------------------

We conducted 1-way sensitivity analysis only on the cost-effective interventions identified in the base case analyses (ie, SG). eFigures 1 to 4 in the [Supplement](#note-ZOI190006-1-s){ref-type="supplementary-material"} show the 10 model parameters for each weight class that had the largest association with the ICER, using tornado diagrams. We found that in patients with mild, moderate, or severe obesity, SG remained cost-effective despite variations in all model inputs. In overweight patients, the ICER for SG remained below the willingness-to-pay threshold (\$100 000/QALY), despite modifications to all model inputs except for age and the hazard ratio for decompensation associated with a 1-U increase in BMI. The ICER rose above \$100 000 per QALY (vs usual care) when age was varied to its high extreme (73.6 years) and when the hazard ratio for decompensation associated with a 1-U increase in BMI was varied to its low extreme (1.01).

In the PSA, model parameters were varied simultaneously 10 000 times, and cost-effectiveness was calculated. According to our PSA results, SG was the most cost-effective option for patients with overweight or obesity in most iterations. In patients with severe obesity, SG was the optimal strategy in 79% of iterations, using a willingness-to-pay threshold of \$100 000 per QALY (eFigure 5 in the [Supplement](#note-ZOI190006-1-s){ref-type="supplementary-material"}). In those with moderate obesity, SG was the most cost-effective option in 64% of iterations (eFigure 6 in the [Supplement](#note-ZOI190006-1-s){ref-type="supplementary-material"}). In patients with mild obesity, it was the most cost-effective option in 76% of iterations (eFigure 7 in the [Supplement](#note-ZOI190006-1-s){ref-type="supplementary-material"}). In the overweight population, SG was the optimal strategy in 53% of model iterations (eFigure 8 in the [Supplement](#note-ZOI190006-1-s){ref-type="supplementary-material"}).

Discussion {#H1-4-ZOI190006}
==========

In this modeling-based study, we examined whether the benefits of bariatric surgery outweighed the heightened risks of mortality and complications in surgical candidates with NASH cirrhosis. Our results projected that surgery would outperform usual care and ILI across all weight classes assessed, including overweight, in terms of life expectancy and QALY. Furthermore, we found that bariatric surgery was cost-effective for patients with obesity (mild, moderate, and severe) and those in the overweight range.

Although studies demonstrate that decompensation is more likely at higher BMIs^[@zoi190006r2]^ and that weight loss leads to decreased portal hypertension in patients with cirrhosis and obesity,^[@zoi190006r5]^ less is known regarding the effect of bariatric surgery on clinical outcomes in NASH cirrhosis.^[@zoi190006r7],[@zoi190006r8]^ In a previous analysis, Klebanoff et al^[@zoi190006r37]^ examined the long-term cost-effectiveness of bariatric surgery in patients with NASH and varying degrees of fibrosis, but that study did not include patients with NASH and cirrhosis. However, given the continued rise in the prevalence of NASH cirrhosis,^[@zoi190006r38]^ we should explore the potential role of weight loss in treating this disease. Therefore, our analysis underscores a real and urgent need for clinical studies of bariatric surgery and other weight loss therapies in NASH cirrhosis.

For patients with obesity, bariatric surgery remained cost-effective in our 1-way sensitivity analyses, which included varying the probability of surgical mortality and complications. These findings are important because the weighing of risks and benefits of bariatric surgery in the setting of cirrhosis may not appear obvious to patients or physicians. Surgery may involve a 3-fold increased risk of death in patients with compensated cirrhosis, compared with those without cirrhosis.^[@zoi190006r9]^ In addition, individuals with cirrhosis have a diminished life expectancy, and thus may not derive long-term health benefits from surgery, including improvements in comorbidities such as hypertension, dyslipidemia, and diabetes.^[@zoi190006r39],[@zoi190006r40]^ Despite these considerations, our analysis suggests that the benefits of surgery may outweigh the risks. In sensitivity analyses, surgery remained cost-effective in patients with obesity, including those with mild obesity (BMI, 30.0-35.0), even when we assumed a small benefit of weight loss on liver disease progression and an increase in the the risk of surgical mortality. In addition, a recent analysis found no association between compensated cirrhosis and increased mortality in patients undergoing bariatric surgery, suggesting that our analysis may even overstate the dangers of bariatric surgery.^[@zoi190006r41]^ Our findings are consistent with the available evidence, suggesting that bariatric surgery offers an acceptably low risk in patients with compensated cirrhosis, potentially even in those with portal hypertension.^[@zoi190006r42],[@zoi190006r43]^

To date, no clinical studies have compared outcomes of SG and GB in patients with NASH cirrhosis. We chose to include both procedures in our model, because they are the 2 most common bariatric procedures performed in the United States.^[@zoi190006r44]^ Of the treatment options in this analysis, GB involved the largest increase in life expectancy and quality of life for patients with obesity, but SG was the most cost-effective. Although GB involved a slightly greater increase in QALYs, it was also marginally more expensive than SG. Our findings suggest that the slightly superior weight loss attributable to GB might not be worth the higher cost of the procedure. In addition to the extra cost of GB, it also entails a higher risk of complications, which may limit its cost-effectiveness. Data from patients without cirrhosis show that GB induces more weight loss and more successful resolution of comorbidities compared with SG, but also involves a higher rate of deep wound infections, serious morbidity, and 30-day reoperation.^[@zoi190006r23]^ Despite the overall lower rate of complications for SG, it is associated with an increased risk of portal vein thrombosis, a rare but serious complication with mortality exceeding 40% among affected patients.^[@zoi190006r45]^ Although this risk poses an important clinical consideration, patients and physicians are increasingly opting for SG, owing to various potential advantages. For example, SG preserves endoscopic access to the gastric tube in the event of variceal bleeding, as well as access to the biliary system.^[@zoi190006r46]^ While our model is informed by limited data and should not be used to guide selection of a particular bariatric procedure, our findings support the idea that SG may provide a more favorable combination of risk, benefit, and cost compared with GB. Given the rapidly increasing popularity of SG at the expense of GB, our results may reflect a growing conventional wisdom concerning these procedures among bariatric surgeons.

Strengths and Limitations {#H2-8-ZOI190006}
-------------------------

Our study has several strengths. This model is, to our knowledge, the first cost-effectiveness analysis of bariatric surgery and lifestyle intervention among patients with NASH cirrhosis. In addition, although 1 previous modeling study explored weight loss in patients with cirrhosis,^[@zoi190006r47]^ it did not assess cost-effectiveness and did not include SG, which is now the most popular bariatric procedure in the United States.^[@zoi190006r48]^ Compared with prior analyses, ours also incorporated not only individuals with severe obesity, but also those with lower baseline BMI.

As with any simulation model, our analysis must be viewed in the context of some limitations. First, we used weight loss data from studies of patients without cirrhosis; weight loss after bariatric surgery may differ between patients with and without cirrhosis. This limitation is not major, because the available data suggest excellent weight loss outcomes for patients with and without cirrhosis.^[@zoi190006r7]^ We also extrapolated long-term trends in BMI using data from the Swedish Obese Subjects study,^[@zoi190006r26]^ given a lack of long-term data surrounding trends in weight after SG and GB. In addition, we assumed that weight loss would slow the progression of compensated cirrhosis to decompensated cirrhosis. This decision gains support from an analysis that described an increased risk of decompensation associated with high BMI,^[@zoi190006r2]^ as well as a trial that found decreased portal hypertension after weight loss.^[@zoi190006r5]^ Evidence also suggests that bariatric surgery induces resolution of noncirrhotic NASH,^[@zoi190006r49]^ and some limited data show that surgery may even cause regression of fibrosis in patients with cirrhosis.^[@zoi190006r8],[@zoi190006r50]^ Future studies that explore the effects of bariatric surgery in this population will confirm or refute our modeling assumptions. We also assumed that weight loss would benefit patients in our model by leading to a decrease in background mortality, a decrease in the probability of decompensation, and an increase in weight-related quality of life. Thus, we may have overestimated the benefit of surgery on survival and quality of life. However, we also did not explicitly model other comorbidities that resolve or improve with weight loss, such as diabetes, hypertension, and dyslipidemia, which may counterbalance any potential overestimation of clinical benefit. In addition, to inform the effect of weight loss on the probability of decompensation, our analysis used data from a study that included a large portion of patients with cirrhosis secondary to viral hepatitis or alcohol use.^[@zoi190006r2]^ Given the association between NASH and obesity, we suspect that weight loss might have an even greater benefit in individuals with NASH. Accordingly, our estimates of the benefits of bariatric surgery in this population may be conservative.

Our results for patients with a BMI of less than 35.0 should also be viewed with some caution. The available evidence suggests that bariatric surgery is safe and does not lead to excessive weight loss in patients with mild obesity. Based on the current literature, the American Society for Metabolic and Bariatric Surgery^[@zoi190006r51]^ and the International Federation for the Surgery of Obesity and Metabolic Disorders^[@zoi190006r52]^ recommend bariatric surgery as an option for suitable patients with a BMI of 30.0 to 35.0. For patients with a BMI of less than 30.0, scant data are available to guide clinical decision making. The lack of data to inform modeling for patients with a BMI of less than 30.0 makes our analysis of the overweight patients an exploratory one, although we can reasonably expect similar beneficial results of surgery in the lower BMI group.

Conclusions {#H1-5-ZOI190006}
===========

Our results underscore the promise that bariatric procedures may hold for patients with NASH cirrhosis, including those with lower BMI. Our analysis affirms that the benefits of surgery likely outweigh the risks in otherwise eligible individuals, and surgery could be a cost-effective intervention. Given the increasing burden of NASH cirrhosis and the lack of effective treatments, it would appear that future studies must explore the effects of bariatric surgery on disease progression in individuals with NASH cirrhosis.
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